TARSUS PHARMACEUTICALS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
TARSUS PHARMACEUTICALS, INC. (TARS) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 7.11 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 7.33M shares, a 0.59% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 7.28M shares, a 1.18% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 7.20M shares, a 25.76% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 5.72M shares, a 45.85% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 6.99M shares, a 0.93% increase from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 6.92M shares, a 7.02% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 6.47M shares, a 45.35% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 4.45M shares, a 99.84% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 7.11M shares 10-Q · filed 2026-08-06 | ||||||
| 2026-03-31 | 7.33M shares 10-Q · filed 2026-05-06 | ||||||
| 2025-12-31 | 6.99M shares 10-K · filed 2026-02-23 | ||||||
| 2025-09-30 | 7.00M shares 10-Q · filed 2025-11-04 | ||||||
| 2025-06-30 | 7.13M shares 10-Q · filed 2026-08-06 | ||||||
| 2025-03-31 | 7.28M shares 10-Q · filed 2026-05-06 | ||||||
| 2024-12-31 | 6.92M shares 10-K · filed 2026-02-23 | ||||||
| 2024-09-30 | 7.02M shares 10-Q · filed 2025-11-04 | 6.95M shares 10-Q · filed 2024-11-13 | |||||
| 2024-06-30 | 7.02M shares 10-Q · filed 2025-08-06 | ||||||
| 2024-03-31 | 7.20M shares 10-Q · filed 2025-05-01 | ||||||
| 2023-12-31 | 6.47M shares 10-K · filed 2026-02-23 | ||||||
| 2023-09-30 | 6.48M shares 10-Q · filed 2024-11-13 | ||||||
| 2023-06-30 | 6.11M shares 10-Q · filed 2024-08-08 | ||||||
| 2023-03-31 | 5.72M shares 10-Q · filed 2024-05-08 | ||||||
| 2022-12-31 | 4.45M shares 10-K · filed 2025-02-25 | 4.45B shares 10-K · filed 2023-03-17 | |||||
| 2022-09-30 | 4.36M shares 10-Q · filed 2022-11-09 | 4.36M shares 10-Q · filed 2023-11-09 | 4.36B shares 10-Q · filed 2022-11-09 | ||||
| 2022-06-30 | 4.19M shares 10-Q · filed 2022-08-11 | 4.19M shares 10-Q · filed 2023-08-10 | 4.19B shares 10-Q · filed 2022-08-11 | ||||
| 2022-03-31 | 3.93M shares 10-Q · filed 2023-05-09 | ||||||
| 2021-12-31 | 2.80B shares 10-K · filed 2023-03-17 | ||||||
| 2021-09-30 | 2.71M shares 10-Q · filed 2022-11-09 | 950.39M shares 10-Q · filed 2022-11-09 | |||||
| 2021-06-30 | 937.65K shares 10-Q · filed 2022-08-11 | 937.65M shares 10-Q · filed 2022-08-11 | |||||
| 2021-03-31 | 632.78K shares 10-Q · filed 2022-05-11 | ||||||
| 2020-12-31 | 2.02B shares 10-K · filed 2022-03-14 | ||||||
| 2020-09-30 | 10.49B shares 10-Q · filed 2020-11-25 | 10.34B shares 10-Q · filed 2020-11-25 | |||||
| 2019-12-31 | 2.32B shares 10-K · filed 2021-03-31 | ||||||
| 2019-09-30 | 2.13B shares 10-Q · filed 2020-11-25 | 2.06B shares 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |